Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramosetron, low-dose midazolam, and their combination for prevention of postoperative nausea and vomiting after thyroidectomy
ACTRN12612000757819Phase 4Not yet recruiting
- Sponsor
- Astellas Pharma
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in postoperative nausea and vomiting (PONV) comparing Ramosetron, Midazolam and Ramosetron + midazolam (3 arms). Primary endpoints: Severity of nausea, Incidence of vomiting and 1 more. Planned start Aug 2012; status: not yet recruiting.
02
Drugs
ramosetronmidazolam
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on ACTRN12612000757819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000757819.